下载掌阅APP，畅读海量书库
立即打开
［1］O′SHAUGHNESSY M M, HOGAN S L, THOMPSON B D, et al. Glomerular disease frequencies by race, sex and region: results from the International Kidney Biopsy Survey [J]. Nephrol Dial Transplant, 2017, 33 (4): 661-669.
［2］MCQUARRIE E P, MACKINNON B, MCNEICE V, et al. The incidence of biopsy-proven IgA nephropathy is associated with multiple socioeconomic deprivation [J]. Kidney Int, 2014, 85 (1): 198-203.
［3］KUMATOWSKA I, JEDRZEJKA D, MALYSKA A, et al. Trends in the incidence of biopsy-proven glomerular diseases in the adult population in central Poland in the years 1990-2010 [J]. Kidney Blood Press Res, 2012, 35 (4): 254-258.
［4］KIRYLUK K, L Y, SANNA-CHERCHI S, et al. Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis [J]. PLoS Genet, 2012, 8 (6): e1002765.
［5］LOMAX-BROWNE H J, VISCONTI A, PUSEY C D, et al. IgA1 Glycosylation Is Heritable in Healthy Twins [J]. J Am Soc Nephrol, 2017, 28 (1): 64-68.
［6］GALE D P, MOLYNEUX K, WIMBURY D, et al. Galactosylation of IgA1 Is Associated with Common Variation in C1GALT1 [J]. J Am Soc Nephrol, 2017, 28 (7): 2158-2166.
［7］QAZI R A, BASTANI B. Co-existence of thin basement membrane nephropathy with other glomerular pathologies; a single center experience [J]. J Nephropathol, 2015, 4 (2): 43-47.
［8］LIU R, HU B, LI Q, et al. Novel genes and variants associated with IgA nephropathy by co-segregating with the disease phenotypes in 10 IgAN families [J]. Gene, 2015, 571 (1): 43-51.
［9］MILILLO A, LA C F. A SPRY2 mutation leading to MAPK/ERK pathway inhibition is associated with an autosomal dominant form of IgA nephropathy [J]. Eur J Hum Genet, 2015, 23 (12): 1673-1678.
［10］COX S N, PESCE F, EL-SAYED J S, et al. Multiple rare genetic variants co-segregating with familial IgA nephropathy all act within a single immune-related network [J]. J Intern Med, 2017, 281 (2): 189-205.
［11］KIRYLUK K, LI Y. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens [J]. Nat Genet, 2014, 46 (11): 1187-1196.
［12］LI M, FOO J N, WANG J Q, et al. Identification of new susceptibility loci for IgA nephropathy in Han Chinese [J]. Nat Commun, 2015, 6: 7270.
［13］KIRYLUK K, LI Y. GWAS for serum galactose-deficient IgA1 implicates critical genes of the O-glycosylation pathway [J]. PLoS Genet, 2017, 13 (2): e1006609.
［14］XIE J, KIRYLUK K, LI Y, et al. Fine Mapping Implicates a Deletion of CFHR1 and CFHR3 in Protection from IgA Nephropathy in Han Chinese [J]. J Am Soc Nephrol, 2016, 27 (10): 3187-3194.
［15］ZHU L, ZHAI Y L, WANG F M, et al. Variants in Complement Factor H and Complement Factor H-Related Protein Genes, CFHR3 and CFHR1, Affect Complement Activation in IgA Nephropathy [J]. J Am Soc Nephrol, 2015, 26 (5): 1195-1204.
［16］ZHAI Y L, MENG S J, ZHU L, et al. Rare Variants in the Complement Factor H-Related Protein 5 Gene Contribute to Genetic Susceptibility to IgA Nephropathy [J]. J Am Soc Nephrol, 2016, 27 (9): 2894-2905.
［17］ZHU L, GUO W Y, SHI SF, et al. Circulating complement factor H-related protein 5 levels contribute to development and progression of IgA nephropathy [J]. Kidney Int, 2018, 94 (1): 150-158.
［18］XU R, FENG S, LI Z, et al. Polymorphism of DEFA in Chinese Han population with IgA nephropathy [J]. Hum Genet, 2014, 133 (10): 1299-1309.
［19］QI Y Y, ZHOU X J, CHENG F J, et al. DEFA gene variants associated with IgA nephropathy in a Chinese population [J]. Genes Immun, 2015, 16 (3): 231-237.
［20］ZHAI Y L, ZHU L, SHI S F, et al. Increased APRIL Expression Induces IgA1 Aberrant Glycosylation in IgA Nephropathy [J]. Medicine (Baltimore), 2016, 95 (11): e3099.
［21］MUTO M, MANFROI B, SUZUKI H, et al. Toll-Like Receptor 9 Stimulation Induces Aberrant Expression of a Proliferation-Inducing Ligand by Tonsillar Germinal Center B Cells in IgA Nephropathy [J]. J Am Soc Nephrol, 2017, 28 (4): 1227-1238.
［22］RING T, PEDERSEN B B, SALKUS G, et al. Use of eculizumab in crescentic IgA nephropathy: proof of principle and conundrum？[J]. Clin Kidney J, 2015, 8 (5): 489-491.
［23］FELLSTROM B C, BARRATT J, COOK H, et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial [J]. Lancet, 2017, 389 (10084): 2117-2127.